Stay updated with breaking news from Code Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Free Report) was the recipient of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 18,600 shares, a decline of 53.5% from the March 31st total of 40,000 shares. Based on an average daily volume of 588,800 shares, […]
TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. TransCode Therapeutics Stock Performance RNAZ stock opened at $0.50 on Tuesday. TransCode Therapeutics has a 52 week low of $0.47 and a 52 […]
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) – HC Wainwright upped their FY2024 EPS estimates for TransCode Therapeutics in a research report issued on Wednesday, April 3rd. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($2.14) per share for the year, up from their prior estimate of ($25.20). HC […]
BOSTON, April 03, 2024 -- TransCode Therapeutics, Inc. , the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for 2023 and...
TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. TransCode Therapeutics Stock Performance Shares of RNAZ traded down $0.01 during trading hours on Wednesday, reaching $0.67. 138,372 shares of the company traded hands, compared to its […]